COVID-19 vaccination and long COVID among 50 years older and above European: The role of chronic multimorbidity

IF 3.5 3区 医学 Q2 GERIATRICS & GERONTOLOGY
Yumeng Gao , Qian Shen , Yuhan Zang , Tongtong Miao , Man Yang , Yaqi Liu , Xiaowei Zheng , Suwen Shen , Wenyan Wu
{"title":"COVID-19 vaccination and long COVID among 50 years older and above European: The role of chronic multimorbidity","authors":"Yumeng Gao ,&nbsp;Qian Shen ,&nbsp;Yuhan Zang ,&nbsp;Tongtong Miao ,&nbsp;Man Yang ,&nbsp;Yaqi Liu ,&nbsp;Xiaowei Zheng ,&nbsp;Suwen Shen ,&nbsp;Wenyan Wu","doi":"10.1016/j.archger.2024.105554","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and aims</h3><p>We aimed to explore the association between coronavirus disease-19 (COVID-19) vaccination and long COVID according to the status of chronic multimobidity.</p></div><div><h3>Methods</h3><p>A total of 1913 participants were recruited in the cross-sectional study on the basis of the Survey of Health and Retirement in Europe. COVID-19 vaccination was defined as vaccination within the last 12 months. Chronic multimorbidity was defined as history of 2 + chronic disease. The study outcome was long COVID during the 12-month follow-up. Multivariable logistic models were performed to estimate the influence of chronic multimorbidity on the association of vaccination with long COVID. Net reclassification improvement (NRI) and integrated discrimination improvement (IDI) were calculated.</p></div><div><h3>Results</h3><p>Chronic multimorbidity significantly modified the association of COVID-19 vaccination with long COVID (<em>P</em><sub>interaction</sub> = 0.024). The rates of study outcome were significantly lower among vaccinated participants in the chronic multimorbidity subgroup, but not in the other subgroup. Multivariable odds ratios (95 % confidence intervals) of study outcome for unvaccination vs. vaccination were 1.494 (1.013–2.203) in those with multimorbidity and 0.915 (0.654–1.280) in those without multimorbidity, respectively. Adding COVID-19 vaccination to a model containing conventional risk factors significantly improved risk reclassification for study outcome among those with chronic multimobidity (continuous NRI was 25.39 % [<em>P</em> = 0.002] and IDI was 0.42 % [<em>P</em> = 0.075])</p></div><div><h3>Conclusion</h3><p>An inverse association of COVID-19 vaccination with long COVID was found among participants with chronic multimorbidity, but not among those without chronic multimorbidity. Chronic multimorbidity might expand the influence of unvaccination on developing long COVID among European aged ≥50 years.</p></div>","PeriodicalId":8306,"journal":{"name":"Archives of gerontology and geriatrics","volume":"126 ","pages":"Article 105554"},"PeriodicalIF":3.5000,"publicationDate":"2024-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of gerontology and geriatrics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0167494324002309","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GERIATRICS & GERONTOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background and aims

We aimed to explore the association between coronavirus disease-19 (COVID-19) vaccination and long COVID according to the status of chronic multimobidity.

Methods

A total of 1913 participants were recruited in the cross-sectional study on the basis of the Survey of Health and Retirement in Europe. COVID-19 vaccination was defined as vaccination within the last 12 months. Chronic multimorbidity was defined as history of 2 + chronic disease. The study outcome was long COVID during the 12-month follow-up. Multivariable logistic models were performed to estimate the influence of chronic multimorbidity on the association of vaccination with long COVID. Net reclassification improvement (NRI) and integrated discrimination improvement (IDI) were calculated.

Results

Chronic multimorbidity significantly modified the association of COVID-19 vaccination with long COVID (Pinteraction = 0.024). The rates of study outcome were significantly lower among vaccinated participants in the chronic multimorbidity subgroup, but not in the other subgroup. Multivariable odds ratios (95 % confidence intervals) of study outcome for unvaccination vs. vaccination were 1.494 (1.013–2.203) in those with multimorbidity and 0.915 (0.654–1.280) in those without multimorbidity, respectively. Adding COVID-19 vaccination to a model containing conventional risk factors significantly improved risk reclassification for study outcome among those with chronic multimobidity (continuous NRI was 25.39 % [P = 0.002] and IDI was 0.42 % [P = 0.075])

Conclusion

An inverse association of COVID-19 vaccination with long COVID was found among participants with chronic multimorbidity, but not among those without chronic multimorbidity. Chronic multimorbidity might expand the influence of unvaccination on developing long COVID among European aged ≥50 years.

50 岁及以上欧洲人接种 COVID-19 疫苗和长期接种 COVID:慢性多病症的作用
背景和目的我们旨在根据慢性多发病的状况,探讨冠状病毒病-19(COVID-19)疫苗接种与长COVID之间的关联。方法在欧洲健康和退休调查的基础上,我们共招募了1913名参与者参与横断面研究。COVID-19疫苗接种定义为过去12个月内的接种情况。慢性多发病的定义是患有 2 种以上慢性疾病。研究结果为 12 个月随访期间的长期 COVID。研究人员采用多变量逻辑模型来估算慢性多发病对接种疫苗与长COVID相关性的影响。结果 慢性多病显著改变了 COVID-19 疫苗接种与长 COVID 的相关性(Pinteraction = 0.024)。在慢性多病亚组中,接种疫苗者的研究结果发生率明显降低,而在其他亚组中则没有明显降低。未接种与接种的多变量研究结果几率比(95 % 置信区间)分别为:多病症者 1.494(1.013-2.203),无多病症者 0.915(0.654-1.280)。在包含常规风险因素的模型中加入 COVID-19 疫苗接种可显著改善慢性多病参与者的研究结果风险再分类(连续 NRI 为 25.39 % [P = 0.002],IDI 为 0.42 % [P = 0.075])。在年龄≥50 岁的欧洲人中,慢性多病可能会扩大未接种疫苗对罹患长COVID的影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
7.30
自引率
5.00%
发文量
198
审稿时长
16 days
期刊介绍: Archives of Gerontology and Geriatrics provides a medium for the publication of papers from the fields of experimental gerontology and clinical and social geriatrics. The principal aim of the journal is to facilitate the exchange of information between specialists in these three fields of gerontological research. Experimental papers dealing with the basic mechanisms of aging at molecular, cellular, tissue or organ levels will be published. Clinical papers will be accepted if they provide sufficiently new information or are of fundamental importance for the knowledge of human aging. Purely descriptive clinical papers will be accepted only if the results permit further interpretation. Papers dealing with anti-aging pharmacological preparations in humans are welcome. Papers on the social aspects of geriatrics will be accepted if they are of general interest regarding the epidemiology of aging and the efficiency and working methods of the social organizations for the health care of the elderly.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信